Eledon Pharmaceuticals, Inc.
NASDAQ:ELDNBiotechnology
+$0.11 today
- Market cap
- $171.45M
- Beta
- 0.97
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.70
Volume 1.12M
Average 1.37M
ELDN Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Eledon Pharmaceuticals, Inc.NASDAQ: ELDN
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$21.18M, compared with -$17.96M a year earlier. Trailing-twelve-month operating income was -$86.47M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -18.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.18M+1.4% QoQ
- Last fiscal yearDec 2025
- -$83.25M-18.0% YoY
- LTMMar 2026
- -$86.47M-11.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -17.9% | +100.0% | +117.9 pp |
| 1 year | -18.0% | +100.0% | +118.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (83.25M) USD
- Year-over-year change
- -18.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (83.25M) | -18.0% |
| FY2024 | 2024-12-31 | (70.58M) | -64.1% |
| FY2023 | 2023-12-31 | (43M) | +51.4% |
| FY2022 | 2022-12-31 | (88.43M) | -139.9% |
| FY2021 | 2021-12-31 | (36.87M) | — |
Operating Income vs competitors
How ELDN compares with its peers on the latest reported figures
- ELDN's LTM Mar 2026 operating income of -$86.47M is the 3rd highest of the 11 companies compared; the peer median is -$121.27M.
- Its year-over-year change of -11.3% is the 4th highest of 11, against a peer median of -18.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.49M | -20.8% | +16.3% | 13.0% | |
| LTM Mar 2026 | -$52.45M | -14.1% | — | — | |
| LTM Mar 2026 | -$86.47M | -11.3% | — | — | |
| LTM Mar 2026 | -$92.75M | -33.3% | — | 637.9% | |
| LTM Mar 2026 | -$113.89M | -2.6% | — | 5649.2% | |
| LTM Mar 2026 | -$115.11M | +55.8% | — | 297.5% | |
| LTM Mar 2026 | -$127.42M | -25.2% | — | 349.2% | |
| LTM Mar 2026 | -$160.36M | -111.1% | — | 73.6% | |
| LTM Mar 2026 | -$178.41M | -4443.0% | — | 3109.3% | |
| LTM Mar 2026 | -$189.85M | -17.1% | — | — | |
| LTM Mar 2026 | -$190.22M | +29.3% | — | — | |
| Peer median (excluding ELDN) | -$121.27M | -18.9% | +16.3% | 349.2% | |
Competitors are the stored peer set for ELDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.74M | 27.08M | 30.31M | 51.96M | 66.27M |
| Selling, General & Admin | 13.13M | 12.7M | 12.69M | 18.61M | 16.98M |
| Operating Expenses | 36.87M | 88.43M | 43M | 70.58M | 83.25M |
| Depreciation & Amortization | 195K | 373K | 374K | 359K | 313K |
| EBITDA | (36.67M) | (39.41M) | (116.16M) | (35.39M) | (45.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (36.87M) | (88.43M) | (43M) | (70.58M) | (83.25M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7K | 462K | (73.54M) | 34.82M | 37.67M |
| Income Before Tax | (36.86M) | (87.97M) | (116.54M) | (35.75M) | (45.58M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.35M) | 0 | 0 | 431K | 35K |
| Net Income | (34.51M) | (87.97M) | (116.54M) | (36.18M) | (45.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| EPS (Diluted) | (2.33) | (6.16) | (4.73) | (0.75) | (0.56) |
| Weighted Avg Shares | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
| Weighted Avg Shares (Diluted) | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M |
Eledon Pharmaceuticals, Inc.
NASDAQ:ELDN
Intrinsic Alpha fair value
Locked
Current Price
$2.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.